Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

ClinicalTrials.gov ID: NCT00551031

Public ClinicalTrials.gov record NCT00551031. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.

Study identification

NCT ID
NCT00551031
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
2,098 participants

Conditions and interventions

Interventions

  • Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1) Biological
  • Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2) Biological
  • Split, Inactivated, Trivalent Influenza Vaccine (Standard dose) Biological
  • Split, Inactivated, Trivalent Influenza Vaccine (High-dose) Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2007
Primary completion
May 31, 2008
Completion
Oct 31, 2008
Last update posted
May 15, 2016

2007 – 2008

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
29
Facility City State ZIP Site status
Not listed Alabaster Alabama
Not listed Mobile Alabama
Not listed Chandler Arizona
Not listed Mesa Arizona
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Fountain Valley California
Not listed San Diego California
Not listed Stanford Connecticut
Not listed Pembroke Pines Florida
Not listed Pinellas Park Florida
Not listed Boise Idaho
Not listed Chicago Illinois
Not listed Wichita Kansas
Not listed Kansas City Missouri
Not listed Springfield Missouri
Not listed St Louis Missouri
Not listed Cary North Carolina
Not listed Raleigh North Carolina
Not listed Cincinnati Ohio
Not listed Allentown Pennsylvania
Not listed Bensalem Pennsylvania
Not listed Warwick Rhode Island
Not listed Goose Creek South Carolina
Not listed Fort Worth Texas
Not listed Galveston Texas
Not listed Salt Lake City Utah
Not listed West Jordan Utah
Not listed Marshfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00551031, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 15, 2016 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00551031 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →